Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Inozyme Pharma Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, focusing the company's immediate prosecution on a single point of contact. The matter is situated in 1 distinct art unit, which indicates a specific technical focus for the current pending application. This concentration allows the legal team to focus their resources on the requirements of a single examination group.
The busiest examiner, BOWERS, ERIN M, is responsible for 1 pending office action. This examiner handles the only active office action for the company at this time. With 1 busiest examiner pending action, the success of the current prosecution cycle depends on the interaction with this specific official. Legal teams should tailor their strategy to the requirements of the assigned art unit and the individual examiner to ensure an efficient path toward allowance. Understanding the specific technical preferences of BOWERS, ERIN M will be critical for resolving the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18612571 | LYOPHILIZED ENPP1 POLYPEPTIDE FORMULATIONS AND USES THEREOF | BOWERS, ERIN M | 1653 | §103§112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInozyme Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erin M Bowers has the most, with 1 of Inozyme Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.